NASDAQ:ANIK - Nasdaq - US0352551081 - Common Stock - Currency: USD
17.39
-0.26 (-1.47%)
The current stock price of ANIK is 17.39 USD. In the past month the price increased by 6.23%. In the past year, price decreased by -32.83%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. The company is headquartered in Bedford, Massachusetts and currently employs 357 full-time employees. The firm creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. The company is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
ANIKA THERAPEUTICS INC
32 Wiggins Ave
Bedford MASSACHUSETTS 01730 US
CEO: Cheryl R. Blanchard
Employees: 357
Company Website: https://anika.com/
Investor Relations: https://ir.anika.com/
Phone: 17814579000
The current stock price of ANIK is 17.39 USD. The price decreased by -1.47% in the last trading session.
The exchange symbol of ANIKA THERAPEUTICS INC is ANIK and it is listed on the Nasdaq exchange.
ANIK stock is listed on the Nasdaq exchange.
8 analysts have analysed ANIK and the average price target is 27.03 USD. This implies a price increase of 55.43% is expected in the next year compared to the current price of 17.39. Check the ANIKA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ANIKA THERAPEUTICS INC (ANIK) has a market capitalization of 254.76M USD. This makes ANIK a Micro Cap stock.
ANIKA THERAPEUTICS INC (ANIK) currently has 357 employees.
ANIKA THERAPEUTICS INC (ANIK) has a support level at 15.57 and a resistance level at 17.45. Check the full technical report for a detailed analysis of ANIK support and resistance levels.
The Revenue of ANIKA THERAPEUTICS INC (ANIK) is expected to decline by -9.03% in the next year. Check the estimates tab for more information on the ANIK EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANIK does not pay a dividend.
ANIKA THERAPEUTICS INC (ANIK) will report earnings on 2025-05-06, after the market close.
ANIKA THERAPEUTICS INC (ANIK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.87).
The outstanding short interest for ANIKA THERAPEUTICS INC (ANIK) is 2.72% of its float. Check the ownership tab for more information on the ANIK short interest.
ChartMill assigns a technical rating of 3 / 10 to ANIK. When comparing the yearly performance of all stocks, ANIK is a bad performer in the overall market: 81.73% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to ANIK. No worries on liquidiy or solvency for ANIK as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ANIK reported a non-GAAP Earnings per Share(EPS) of -4.87. The EPS decreased by -235.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -42.14% | ||
ROE | -54.22% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 88% to ANIK. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 50.41% and a revenue growth -9.03% for ANIK